Nuvisertib (TP-3654) (PIM kinase inhibitor for myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-14 — A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis: Phase 1/2 multicenter, open-label, dose-escalation trial evaluating safety, tolerability, PK, and PD of oral nuvisertib (TP-3654), a first-in-class PIM kinase inhibitor, in patients with intermediate or high-risk primary or secondary myelofibrosis (trial-early). (novelty: 4)
Open questions
Related
Contributing findings
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
14-apr-2026
novelty 4
per-area 4
introduces